Q-omics provides the consensus-scored MIR548N profile across patient tissues and cancer cell-line models. MIR548N expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR548N is differentially expressed in 7, with the highest sampling consensus in STAD. Additionally, MIR548N RNA expression shows 7,355 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight KIRC, STAD, and LIHC as cancer lineages where MIR548N shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR548N — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR548N survival associations across molecular data types. MIR548N RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR548N RNA expression–survival associations across cancer types. High MIR548N expression shows unfavorable associations in KIRC, LGG, STAD, PAAD, MESO and PCPG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR548N RNA expression.
This table summarizes MIR548N tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR548N. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR548N shows lower tumor expression in READ and higher tumor expression in STAD, CHOL, ESCA, KICH and HNSC. The STAD box plot shows higher MIR548N RNA expression in tumor versus normal tissue (log2 FC = +0.430, t-test p = .008).
This table shows molecular features associated with MIR548N in patient tissues and cancer cell lines. In patient samples, MIR548N shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
